The strong effect of the CXCR2 antagonist SB225002 on angiogenesis and the chemokinetic behavior of endothelial cells suggests a high efficacy which corroborates our previous findings in a murine GBM model [21]. The gene discussed is CXCR2; the disease is glioblastoma.